Accelovance
2275 Research Boulevard
Suite 700
Rockville
Maryland
20850
United States
Tel: 240-238-4900
Fax: 240-238-4901
Website: http://www.accelovance.com/
Email: info@accelovance.com
About Accelovance
Accelovance, Inc., based in Rockville, MD, is a clinical services company specializing in high patient throughput from recruitment through study completion. Accelovance has developed a model to increase the reliability and productivity on Phase I (outpatient) and Phase II-IV trials. Accelovance enhances this offering with flexible CRO services to meet a Sponsor’s specific trial needs.
Each study is approached with the intent to complete enrollment BEFORE the study starts. With critical planning and full control of patient recruitment and clinical facility operations, Accelovance is committed to delivering high quality, predictable, and cost effective clinical trials.
Accelovance (China) Corp., Ltd., a wholly foreign owned enterprise of Accelovance, Inc., is a clinical CRO and market commercialization services company with offices in Beijing and Shanghai, P.R. China. Accelovance (China) fully leverages its relationship with its parent company, U.S. to deliver high quality clinical services in compliance with international standards. In addition, Accelovance (China) works with sponsors to realize the value of the China pharmaceutical market, which is the fastest growing in the world.
29 articles about Accelovance
-
Linical and Accelovance Unite Under Linical Name and Appoint New CEO
7/26/2018
Linical and Accelovance recently merged to create a leading midsized, global contract research organization (CRO).
-
Accelovance & Linical Merge Organizations to Form a Best-in-Class CRO with Increased Global Reach
3/27/2018
Accelovance Inc. announced that it has signed a merger agreement with Linical, a leading CRO based in Asia in the fields of oncology, immunology, and neurology.
-
Accelovance Selected To Advance Immunicum’s INTUVAX Oncology Immunotherapy Pipeline
5/20/2016
-
Accelovance Continues Geographic And Service Expansion With Acquisition Of Clinquest & BV
12/2/2015
-
Accelovance And FHI 360 Enhance Service Offering Through International Strategic Alliance
11/3/2015
-
Accelovance Continues Oncology Leadership Growth With Addition Of Former Global VP, Oncology From Wyeth/Pfizer And Bayer
9/30/2015
-
Midwest Melanoma Partnership And Accelovance Enhance Melanoma Research Offering Through Strategic Alliance
9/15/2015
-
Accelovance Will Create 70 Jobs at New European HQ
8/12/2015
-
Accelovance Completes Trial Enrollment And Delivery Of Clinical Data For Heron' Phase 3 Trial
7/7/2015
-
Accelovance Expands Capabilities In Europe With Acquisition Of Altair Clinical, Ltd.
2/5/2015
-
Accelovance Selects USAN’s All-Inclusive Hosted Contact Center Suite for Clinical Research Study
9/24/2013
-
Accelovance Primed to Achieve Leadership in Oncology Clinical Trials
7/11/2013
-
Sixth Consecutive "Best CRO" Award Nomination for Accelovance
3/27/2013
-
Accelovance Expansion Continues With Acquisition of Radiant Development, the CRO Division of Radiant Research
3/7/2013
-
Accelovance Expands Oncology Leadership With the Addition of Ralph Boccia, MD as Oncology Medical Director
3/1/2013
-
Accelovance Strengthens Executive Team with Chief Medical Officer
11/14/2011
-
Continued Recognition for Excellence; Accelovance Named 2011 "Best CRO"
4/19/2011
-
Accelovance Reports 2010 Growth; Shares Outlook for 2011
2/18/2011
-
Accelovance Named 2010 BEST CRO; Repeat Recognition for Vaccine Excellence
4/27/2010
-
Accelovance Prepares for Continued Growth; Adds to Senior Management Team
2/16/2010